HUT64696A - Method for production of preparations containing diphenyl-butyl-piperazine-carboxamides for the treatment of drug addict and drug abuse - Google Patents

Method for production of preparations containing diphenyl-butyl-piperazine-carboxamides for the treatment of drug addict and drug abuse

Info

Publication number
HUT64696A
HUT64696A HU9203632A HU9203632A HUT64696A HU T64696 A HUT64696 A HU T64696A HU 9203632 A HU9203632 A HU 9203632A HU 9203632 A HU9203632 A HU 9203632A HU T64696 A HUT64696 A HU T64696A
Authority
HU
Hungary
Prior art keywords
piperazine
drug
butyl
carboxamides
treatment
Prior art date
Application number
HU9203632A
Other languages
English (en)
Other versions
HU217833B (hu
Inventor
Anders Bjoerk
Erik Christensson
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of HUT64696A publication Critical patent/HUT64696A/hu
Publication of HU217833B publication Critical patent/HU217833B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
HU9203632A 1991-03-22 1992-03-23 Eljárás difenil-butil-piperazin-karboxamidokat tartalmazó, mértéktelen szerfogyasztásból eredő betegségek kezelésére alkalmas gyógyszerkészítmények előállítására HU217833B (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9100860A SE9100860D0 (sv) 1991-03-22 1991-03-22 New use

Publications (2)

Publication Number Publication Date
HUT64696A true HUT64696A (en) 1994-02-28
HU217833B HU217833B (hu) 2000-04-28

Family

ID=20382242

Family Applications (2)

Application Number Title Priority Date Filing Date
HU9203632A HU217833B (hu) 1991-03-22 1992-03-23 Eljárás difenil-butil-piperazin-karboxamidokat tartalmazó, mértéktelen szerfogyasztásból eredő betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
HU9203632A HU9203632D0 (en) 1991-03-22 1992-03-23 Method for utilization of diphenyl-butyl-piperazine-carboxamides in treatment of diseases of material-dependency

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU9203632A HU9203632D0 (en) 1991-03-22 1992-03-23 Method for utilization of diphenyl-butyl-piperazine-carboxamides in treatment of diseases of material-dependency

Country Status (24)

Country Link
US (2) US5434156A (hu)
EP (1) EP0538422B1 (hu)
JP (1) JP3221611B2 (hu)
KR (1) KR100196674B1 (hu)
AT (1) ATE199057T1 (hu)
AU (1) AU653797B2 (hu)
BG (1) BG61829B1 (hu)
BR (1) BR9204969A (hu)
CA (1) CA2083505C (hu)
CZ (1) CZ282222B6 (hu)
DE (1) DE69231680T2 (hu)
DK (1) DK0538422T3 (hu)
EE (1) EE02973B1 (hu)
ES (1) ES2154261T3 (hu)
GR (1) GR3035805T3 (hu)
HU (2) HU217833B (hu)
IE (1) IE920920A1 (hu)
NO (1) NO301311B1 (hu)
PT (1) PT100279B (hu)
RO (1) RO109702B1 (hu)
RU (1) RU2095062C1 (hu)
SE (1) SE9100860D0 (hu)
SK (1) SK279237B6 (hu)
WO (1) WO1992016211A1 (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
SE9201239D0 (sv) 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
JP3571114B2 (ja) * 1995-07-11 2004-09-29 ポーラ化成工業株式会社 麻薬拮抗剤
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US6090780A (en) * 1999-04-07 2000-07-18 Chandon Prasad Histidyl-proline diketopiperazine and method of use
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
ATE338575T1 (de) * 2001-01-17 2006-09-15 Hythiam Inc Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit
ES2287255T3 (es) * 2001-02-15 2007-12-16 Hythiam, Inc. Uso de flumazenil para producir un medicamento parta el tratamiento de la dependencia a cocaina.
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP2005522436A (ja) 2002-02-08 2005-07-28 グラクソ　グループ　リミテッド ピペリジルカルボキシアミド誘導体またはそのタキキニン介在疾患の治療における使用
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
CA2563743A1 (en) * 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders ii
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
WO2006024471A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006096435A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006119884A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
US20060264512A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunction due to medical conditions
JP2008540673A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤誘発性性機能不全の治療方法
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
WO2007048803A1 (en) * 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
BRPI0712039A2 (pt) * 2006-05-09 2011-12-20 Boehringer Ingelheim Int uso de flibanserina para o tratamento de distúrbios de desejo sexual pós-menopausa
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
EP2043648A1 (en) * 2006-07-14 2009-04-08 Boehringer Ingelheim International GmbH Use of flibanserin for the treatment of sexual disorders in females
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
BRPI0716439B8 (pt) 2006-08-14 2021-05-25 Boehringer Ingelheim Int sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos
BRPI0716436B8 (pt) * 2006-08-25 2021-05-25 Boehringer Ingelheim Int sistema de liberação controlada e método para fabricação do mesmo
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use

Also Published As

Publication number Publication date
HU9203632D0 (en) 1993-03-29
JPH05507731A (ja) 1993-11-04
NO301311B1 (no) 1997-10-13
PT100279A (pt) 1993-07-30
SK279237B6 (sk) 1998-08-05
CA2083505C (en) 2003-06-10
JP3221611B2 (ja) 2001-10-22
NO924502L (no) 1992-11-23
SK344992A3 (en) 1995-11-08
SE9100860D0 (sv) 1991-03-22
KR100196674B1 (ko) 1999-06-15
BG97108A (bg) 1994-03-24
NO924502D0 (no) 1992-11-23
DK0538422T3 (da) 2001-05-07
BG61829B1 (bg) 1998-07-31
RU2095062C1 (ru) 1997-11-10
US5618817A (en) 1997-04-08
EP0538422B1 (en) 2001-02-07
WO1992016211A1 (en) 1992-10-01
RO109702B1 (ro) 1995-05-30
KR930700108A (ko) 1993-03-13
GR3035805T3 (en) 2001-07-31
PT100279B (pt) 1999-06-30
CZ282222B6 (cs) 1997-06-11
CA2083505A1 (en) 1992-09-23
ATE199057T1 (de) 2001-02-15
AU1428092A (en) 1992-10-21
IE920920A1 (en) 1992-09-23
CZ344992A3 (en) 1994-02-16
ES2154261T3 (es) 2001-04-01
AU653797B2 (en) 1994-10-13
DE69231680T2 (de) 2001-06-07
BR9204969A (pt) 1993-07-27
DE69231680D1 (de) 2001-03-15
EP0538422A1 (en) 1993-04-28
EE02973B1 (et) 1997-04-15
HU217833B (hu) 2000-04-28
US5434156A (en) 1995-07-18

Similar Documents

Publication Publication Date Title
HU9203632D0 (en) Method for utilization of diphenyl-butyl-piperazine-carboxamides in treatment of diseases of material-dependency
BG97678A (en) Beta -carotene and/or vitamin e therapy for inhibition of major vascular events
HU9401107D0 (en) Enhanced skin penetration system for improved topical delivery of drugs
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
DE3778008D1 (de) Ketonderivate als arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
AU5170499A (en) Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis
WO2005011579A3 (en) Treatment of dependence withdrawal
CA2118512A1 (en) Agents for treating substance abuse disorders
RO116771B1 (ro) Metodă pentru prevenirea sau tratamentul dependenţei, toleranţei sau abuzului de benzodiazepine
ES2096207T3 (es) Prevencion y tratamiento de aterosclerosis.
EP0290262A3 (en) Improved nitrate therapy for angina pectoris
NZ332484A (en) use of pyridyl and pyrimidyl substituted piperazine derivatives for treating substance abuse disorders
GB8928609D0 (en) Pharmaceutical composition
MY104932A (en) Immunomodulatory azaspiranes
UA29325A (uk) Спосіб профілактики і лікування карієсу зубів у дітей
UA30956A (uk) Спосіб лікування алергічного риніту
UA11050C2 (uk) Спосіб лікуваhhя іhфаркту міокарда в гострому періоді
ES2177697T3 (es) Uso de compuestos de piperacina como antagonista de narcoticos.

Legal Events

Date Code Title Description
DGB9 Succession in title of applicant

Owner name: PHARMACIA & UPJOHN AKTIEBOLAG, SE

HPC4 Succession in title of patentee

Owner name: BIOVITRUM AB, SE

MM4A Lapse of definitive patent protection due to non-payment of fees